Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Janssen to Discontinue Pimodivir Influenza Development Program
Details : Results from pre-planned interim analyses of the Phase 3 pimodivir trial in hospitalised influenza A patients indicate pimodivir in conjunction with the standard of care is unlikely to demonstrate additional benefit in hospitalised influenza A patients c...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 02, 2020
Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
